Stroke drug dosing trial aims to improve recovery for thousands

NCT ID NCT06320431

Recruiting now Disease control Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial is testing two different doses of the clot-busting drug tenecteplase in 4,000 people who have had an acute ischemic stroke. The goal is to find out which dose works best and is safest, especially for patients who have taken blood thinners or are undergoing a procedure to remove the clot. Researchers will track patients for 90 days to see how well they recover and whether they have any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tenecteplase (a clot-busting drug)
What this could lead to: If successful, this trial could identify the safest and most effective dose of tenecteplase for different stroke patients, potentially improving recovery and reducing disability.
What could go wrong: This is an early-phase study with 4,000 participants, and results may not apply to all stroke patients. There is a risk of bleeding, a known side effect of clot-busting drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE (AIS) STROKE, ACUTE STROKE, ACUTE, STROKE ISCHEMIC

Contacts and locations

Locations

Brandon Regional Hospital
NOT_YET_RECRUITING

Brandon, Manitoba, Canada
CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke)
NOT_YET_RECRUITING

Sherbrooke, Quebec, Canada
Centre Hospitalier de l'Université de Montréal (CHUM)
NOT_YET_RECRUITING

Montreal, Quebec, Canada
Health Sciences North Horizon Sante-Nord
RECRUITING

Greater Sudbury, Ontario, Canada
Kelowna Regional Hospital
NOT_YET_RECRUITING

Kelowna, British Columbia, Canada
Kingston General Hospital
NOT_YET_RECRUITING

Kingston, Ontario, Canada
Lawson Health Research Institute- London
NOT_YET_RECRUITING

London, Ontario, Canada
McMaster University Hamilton Health Sciences Centre
RECRUITING

Hamilton, Ontario, Canada
Medicine Hat Regional Hospital
NOT_YET_RECRUITING

Medicine Hat, Alberta, Canada
Monash University (Box Hill)
RECRUITING

Melbourne, Victoria, Australia
Queen Elizabeth Hospital (PEI)
RECRUITING

Charlottetown, Prince Edward Island, Canada
Queen Elizabeth II Health Science Center (Halifax)
NOT_YET_RECRUITING

Halifax, Nova Scotia, Canada
Red Deer Regional Hospital
NOT_YET_RECRUITING

Red Deer, Alberta, Canada
Royal Columbian Hospital
NOT_YET_RECRUITING

New Westminster, British Columbia, Canada
Royal Prince Alfred Hospital
RECRUITING

Sydney, New South Wales, Australia
Royal University Hospital
RECRUITING

Saskatoon, Saskatchewan, Canada
St. Michael's Hospital
RECRUITING

Toronto, Ontario, Canada
Sunnybrook Health Science Centre
RECRUITING

Toronto, Ontario, Canada
The George Institute for Global Health
NOT_YET_RECRUITING

Sydney, Barangaroo, NSW 2000, Australia
University of Alberta
RECRUITING

Edmonton, A, Canada
University of British Columbia
RECRUITING

Vancouver, British Columbia, Canada
University of Calgary
RECRUITING

Calgary, Alberta, T2N 1N4, Canada
University of Manitoba - Winnipeg Health Science Centre
RECRUITING

Winnipeg, Manitoba, Canada
University of Ottawa
RECRUITING

Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.